Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.
2.

Evaluation of Pump Discontinuation and Associated Factors in the T1D Exchange Clinic Registry.

Wong JC, Boyle C, DiMeglio LA, Mastrandrea LD, Abel KL, Cengiz E, Cemeroglu PA, Aleppo G, Largay JF, Foster NC, Beck RW, Adi S; T1D Exchange Clinic Network.

J Diabetes Sci Technol. 2017 Mar;11(2):224-232. doi: 10.1177/1932296816663963. Epub 2016 Sep 25.

PMID:
27595711
3.

A Comparison of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Insulin Injection in Children with Type I Diabetes in Kuwait: Glycemic Control, Insulin Requirement, and BMI.

Majedah M. AbdulRasoul, Mousa M, Al-Mahdi M, Al-Sanaa H; Dalia Al-AbdulRazzaq, Al-Kandari H.

Oman Med J. 2015 Sep;30(5):336-43. doi: 10.5001/omj.2015.69.

4.

Study protocol for a randomised controlled trial of insulin delivery by continuous subcutaneous infusion compared to multiple daily injections.

Blair J, Gregory JW, Hughes D, Ridyard CH, Gamble C, McKay A, Didi M, Thornborough K, Bedson E, Awoyale L, Cwiklinski E, Peak M.

Trials. 2015 Apr 16;16:163. doi: 10.1186/s13063-015-0658-5.

5.

The effectiveness and durability of an early insulin pump therapy in children and adolescents with type 1 diabetes mellitus.

Brancato D, Fleres M, Aiello V, Saura G, Scorsone A, Ferrara L, Provenzano F, Di Noto A, Spano L, Provenzano V.

Diabetes Technol Ther. 2014 Nov;16(11):735-41. doi: 10.1089/dia.2014.0034. Epub 2014 Aug 27.

6.

Diabetes self-care and the older adult.

Weinger K, Beverly EA, Smaldone A.

West J Nurs Res. 2014 Oct;36(9):1272-98. doi: 10.1177/0193945914521696. Epub 2014 Feb 7. Review.

7.

The evidence base for diabetes technology: appropriate and inappropriate meta-analysis.

Pickup JC.

J Diabetes Sci Technol. 2013 Nov 1;7(6):1567-74. Review.

8.

New technologies for diabetes: a review of the present and the future.

Ramchandani N, Heptulla RA.

Int J Pediatr Endocrinol. 2012 Oct 26;2012(1):28. doi: 10.1186/1687-9856-2012-28.

9.

Long-term efficacy of insulin pump therapy in children with type 1 diabetes mellitus.

Batajoo RJ, Messina CR, Wilson TA.

J Clin Res Pediatr Endocrinol. 2012 Sep;4(3):127-31. doi: 10.4274/Jcrpe.751.

10.

Quality of life and technology: impact on children and families with diabetes.

Hirose M, Beverly EA, Weinger K.

Curr Diab Rep. 2012 Dec;12(6):711-20. doi: 10.1007/s11892-012-0313-4. Review.

11.

Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors.

Brod M, Valensi P, Shaban JA, Bushnell DM, Christensen TL.

Qual Life Res. 2010 Nov;19(9):1285-93. doi: 10.1007/s11136-010-9699-0. Epub 2010 Jul 4.

12.

Parental involvement buffers associations between pump duration and metabolic control among adolescents with type 1 diabetes.

Wiebe DJ, Croom A, Fortenberry KT, Butner J, Butler J, Swinyard MT, Lindsay R, Donaldson D, Foster C, Murray M, Berg CA.

J Pediatr Psychol. 2010 Nov;35(10):1152-60. doi: 10.1093/jpepsy/jsq012. Epub 2010 Mar 10.

13.
14.

Autonomy and insulin in adolescents with type 1 diabetes.

Comeaux SJ, Jaser SS.

Pediatr Diabetes. 2010 Nov;11(7):498-504. doi: 10.1111/j.1399-5448.2009.00625.x. Review. No abstract available.

15.
17.

Past, present, and future of insulin pump therapy: better shot at diabetes control.

Sherr J, Tamborlane WV.

Mt Sinai J Med. 2008 Aug;75(4):352-61. doi: 10.1002/msj.20055. Review.

18.

Supplemental Content

Support Center